Genetics Research, published by HINDAWI LTD, is a distinguished open access journal that has been at the forefront of genetic studies since its inception in 1960. With the transition to open access in 2019, this journal has expanded its accessibility, fostering knowledge dissemination across the global scientific community. Operating out of the United Kingdom, it provides a platform for innovative research in the fields of genetics and molecular biology, encompassing a broad range of topics that are highly relevant to medical sciences. As of 2023, it holds a Q4 classification in Genetics and a Q3 classification in miscellaneous Medicine, reflecting its ongoing commitment to scholarly excellence amidst shifting academic landscapes. While the journal's H-index remains unlisted, its indexed ranking within Scopus, with a rank of #325/328 in the Genetics category highlights the challenges ligated to its niche audience. Nevertheless, it serves as a crucial resource for researchers, professionals, and students eager to contribute to and stay informed on the latest genetic research trends and breakthroughs.

Human Genome Variation, published by SpringerNature, is an esteemed open access journal dedicated to the field of genetic research and exploration. Since its inception in 2014, the journal has been at the forefront of advancing our understanding of human genome diversity and its implications in health and disease. With an E-ISSN of 2054-345X, it features a diverse array of studies that encompass biochemistry, genetics, and molecular biology, making it an invaluable resource for researchers and professionals alike. The journal holds a Q3 ranking in both biochemistry and genetics, and a Q4 ranking in molecular biology, highlighting its growing influence within these disciplines. As the landscape of genomics continues to evolve, Human Genome Variation serves as a platform for the dissemination of high-quality research, fostering collaboration and innovation within the scientific community. Researchers and academics are invited to contribute to this pivotal journal, which not only provides open access to its content since 2014 but also aims to bridge the gap between basic research and clinical applications in genetics.

Cardiogenetics, published by MDPI, is a leading open-access journal dedicated to advancing the field of genetics as it pertains to cardiovascular health and diseases. Since its launch in 2011, this journal has been at the forefront of disseminating high-quality research that explores the genetic underpinnings of cardiovascular conditions, offering a platform for innovative studies, reviews, and case reports. With an ISSN of 2035-8253 and an E-ISSN of 2035-8148, Cardiogenetics aims to bridge the gap between genetic research and clinical application, helping researchers, healthcare professionals, and students stay abreast of the latest advancements and findings. The journal’s commitment to open access ensures that its valuable content is available to a global audience, fostering greater collaboration and knowledge sharing in the cardiovascular genetics community. By contributing to this dynamic field, Cardiogenetics plays a crucial role in improving patient outcomes and paving the way for personalized medicine in cardiology.

CLINICAL PHARMACOKINETICS, published by ADIS INT LTD, is a premier journal dedicated to the field of pharmacology, with a distinguished reputation since its inception in 1976. With an impressive impact factor and categorized in the Q1 quartile for both general pharmacology and medical pharmacology, this journal ranks #29 out of 272 and #53 out of 313 in its respective categories in Scopus, highlighting its high academic influence and the quality of research it publishes. CLINICAL PHARMACOKINETICS serves as a vital resource for researchers, professionals, and students interested in the latest advancements in drug metabolism, therapeutic efficacy, and clinical applications of pharmacokinetic studies. As it continues to evolve through 2024 and beyond, the journal remains committed to fostering a deeper understanding of pharmacotherapy and its implications in clinical practice. While it does not currently offer open access, the journal ensures that cutting-edge research is accessible through various academic platforms.

The Journal of Hepatocellular Carcinoma is a pivotal open-access publication dedicated to advancing the field of hepatocellular carcinoma research. Published by DOVE MEDICAL PRESS LTD since 2014, this journal seeks to disseminate high-quality articles that explore innovative treatments, clinical trials, and emerging research in the context of liver cancer. With its ISSN: N/A and E-ISSN: 2253-5969, the journal is optimized for a global audience, ensuring accessibility to a broad spectrum of researchers, healthcare professionals, and students engaged in oncology and hepatology. While its Scopus ranking places it in the lower quartiles of the respective fields, the journal continues to strive for growth and visibility in a rapidly evolving landscape. The Journal of Hepatocellular Carcinoma is an essential resource for anyone seeking to enhance their understanding of liver diseases and contribute to the fight against hepatocellular carcinoma.

FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Pharmakopsychiatry is a distinguished journal published by Georg Thieme Verlag KG that has been at the forefront of research since its inception in 1984. This peer-reviewed journal, with an ISSN of 0176-3679 and E-ISSN of 1439-0795, occupies a pivotal role in the field of medicine, focusing on the intricate intersections of pharmacology, psychiatry, and mental health. Its robust academic standing is demonstrated by its Q2 quartile rankings across multiple categories, including Medicine (miscellaneous) and Psychiatry and Mental Health, showcasing its significant influence with Scopus ranks placing it in the 80th percentile for Psychiatry and Mental Health. Pharmakopsychiatry aims to disseminate cutting-edge research that advances our understanding of pharmacological treatments in psychiatric practice, catering to a diverse audience of researchers, clinicians, and students. With an unwavering commitment to high-quality scholarship and its strategic location in Germany, this journal is an essential resource for those seeking to stay abreast of emerging trends and methodologies in the field.

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.